Nancy Cox, Ph.D., founding director of the Vanderbilt Genetics Institute, will deliver the next Flexner Discovery Lecture on Thursday, Dec. 17.

Vanderbilt University researchers next month will launch a major initiative to acquire “dense genotypes” from 100,000 individuals whose medical histories are known.

As of last week, Vanderbilt has updated the process used to facilitate patient participation in BioVU, the Medical Center’s DNA repository.

Vanderbilt’s biobank, BioVU, has begun to collect and store plasma, the liquid part of blood, to aid studies of diseases ranging from heart failure and hypertension to breast cancer.

A person’s mitochondrial gene “signature” could predict risk for diabetic retinopathy and guide early intervention strategies.

Vanderbilt University has formed a scientific partnership with Celgene Corporation to investigate new uses for the company’s anti-inflammatory drugs that are already on the market.

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH).